Safety and pharmacokinetics of XOMA 3AB, A novel mixture of three monoclonal antibodies against botulinum toxin A

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5047-5053

  Nayak, S U ^a   Griffiss, J M ^b   McKenzie, R ^a   Fuchs, E J ^a   Jurao, R A ^a   An, A T ^a,d   Ahene, A ^c   Tomic, M ^c   Hendrix, C W ^a   Zenilman, J M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Clinical RM Inc   (United States)

^c XOMA Corporation   (United States)

^d ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; BOTULINUM ANTISERUM; BOTULINUM TOXIN A; CREATINE KINASE; GLUCOSE; HEMOGLOBIN; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; XOMA 3AB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CHEMISTRY; BLOOD EXAMINATION; BOTULISM; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNOGENICITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOKINETICS; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MOUSE; YOUNG ADULT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MICE; YOUNG ADULT;

EID: 84906098671     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02830-14     Document Type: Article

References (19)

1. Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291:1091-1104. http://dx.doi.org/10. 1006/jmbi.1999.2945. (Pubitemid 29423772)
2. Barash JR, Arnon SS. 2014. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 209:183-191. http://dx.doi.org/10.1093/infdis/jit449.
3. Centers for Disease Control and Prevention. 1998. Botulism in the United States 1899-1996. In Handbook for epidemiologists, clinicians and laboratory workers. Centers for Disease Control and Prevention, Atlanta, GA.
4. Dembek ZF, Smith LA, Rusnak JM. 2007. Botulism: cause, effects, diagnosis, clinical and laboratory identification and treatment modalities. Disaster Med. Public Health Prep. 1:122-134. http://dx.doi.org/10.1097/DMP. 0b013e318158c5fd.
5. Arnon SS, Schecter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285: 1059-1070. http://dx.doi.org/10.1001/jama.285.8. 1059. (Pubitemid 32176420)
6. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. 2006. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 362:733-742. http://dx.doi.org/10.1016/j.jmb.2006.07.040. (Pubitemid 44404084)
7. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svennsson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. 2007. Genetic diversity among botulinum neurotoxin producing clostridial strains. J. Bacteriol. 189: 818 - 832. http://dx.doi.org/10.1128/JB.01180-06.
8. St John R, Finlay B, Blair C. 2001. Bioterrorism in Canada: an economic assessment of prevention and postattack response. Can. J. Infect. Dis. 12:275-284. (Pubitemid 33111425)
9. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. 1993. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalational botulism, p 473- 476. In DasGupta BR (ed), Botulinum and tetanus neurotoxins: neurotransmission and biochemical aspects. Plenum, New York, NY.
10. Arnon SS, Schecter R, Maslanka SE, Jewell NP, Hatheway CL. 2006. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 354:462-471. http://dx.doi.org/10.1056/NEJMoa051926. (Pubitemid 43200297)
11. Black RE, Gunn RA. 1980. Hypersensitivity reactions associated with botulinal antitoxin. Am. J. Med. 69:567-570. http://dx.doi.org/10.1016/0002- 9343(80)90469-6. (Pubitemid 10018712)
12. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 99:11346-11350. http://dx.doi.org/10.1073/pnas.172229899. (Pubitemid 34920928)
13. Pless DD, Torres ER, Reinke EK, Bavari S. 2001. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect. Immun. 69:570-574. http://dx.doi.org/10.1128/IAI.69.1.570-574.2001. (Pubitemid 32040950)
14. XOMACorporation. 2012.XOMA3AB: investigator's brochure, version 3.0. XOMA, Berkeley, CA.
15. National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases Office of Clinical Research Affairs. 2011. Establishing criteria for volunteer participation in DMID clinical research. National Institute of Allergy and Infectious Diseases, Rockville, MD.
16. Meng Q, Garcia-Rodriquez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD. 2012. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal. Biochem. 430:141-150. http://dx.doi.org/10.1016/j.ab.2012.08.005.
17. Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD. 2006. Serum creatinine kinase levels and renal function measures in exertional muscle damage. Med. Sci. Sports Exerc. 38:623-627. http://dx.doi.org/10.1249/01.mss. 0000210192.49210.fc.
18. Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkstrom V, Ekelund M. 2008. Muscular exercise can cause highly pathological liver function tests in healthy men. Br. J. Clin. Pharmacol. 65:253-259. http://dx.doi.org/10.1111/j.1365-2125.2007.03001.x. (Pubitemid 351171267)
19. Broussard LA. 2001. Biological agents: weapons of warfare and bioterrorism. Mol. Diagn. 6:323-333. (Pubitemid 34042380)